Quercetin has the most extensive human clinical trial database of any flavonoid senolytic. Consistent findings include: blood pressure reduction (confirmed in 7 RCTs), CRP reduction (confirmed in 4 meta-analyses), LDL oxidation reduction (consistent across 5 trials), and — in the D+Q senolytic context — measurable reduction of senescent cell biomarkers (PMID: 30559422).

Why do some quercetin RCTs show no effect?

Studies using low-dose (< 200 mg/day) standard quercetin aglycone often find no significant effects — consistent with the poor bioavailability of this form. Studies using ≥500 mg/day or phytosome forms consistently show benefits.

What is the best-quality quercetin RCT?

The Xu et al. (Nature Medicine 2018) D+Q trial is considered the highest-impact quercetin clinical study for aging. For cardiovascular evidence, the Larson et al. (2012) crossover RCT in arterial stiffness is a landmark reference.